FDA approves Lucentis to treat Diabetic Retinopathy associated with DME- Genetech + Novartis
Genentech, a member of the Roche Group announced that the FDA approved Lucentis (ranibizumab injection) for the treatment of Diabetic Retinopathy (DR) in people with Diabetic Macular Edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. The FDA granted Lucentis Breakthrough Therapy Designation and Priority Review for this indication based on results from the RISE and RIDE Phase III clinical trials. While there are various options for treating Diabetic Macular Edema, none were approved showing improvement in retinopathy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.